International multicentre, randomised phase III clinical trials have shown that BCL2 overexpression or c‐Myc and BCL2 co‐overexpression (double hits)15 was significantly associated with poor clinical outcomes and high relapse/refractory rates in patients with DLBCL and was an independent prognostic biomarker for evaluating overall and progression‐free survival of patients with DLBCL following R‐CHOP treatment.16 This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.